Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharma LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50p -3.82% 63.00p 98,064 16:07:06
Bid Price Offer Price High Price Low Price Open Price
61.00p 65.00p 65.00p 60.50p 65.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -18.72 -67.54 19.5

Faron Pharma (FARN) Latest News

More Faron Pharma News
Faron Pharma Takeover Rumours

Faron Pharma (FARN) Share Charts

1 Year Faron Pharma Chart

1 Year Faron Pharma Chart

1 Month Faron Pharma Chart

1 Month Faron Pharma Chart

Intraday Faron Pharma Chart

Intraday Faron Pharma Chart

Faron Pharma (FARN) Discussions and Chat

Faron Pharma Forums and Chat

Date Time Title Posts
07/12/201814:21Respite for ARDS sufferers1,097

Add a New Thread

Faron Pharma (FARN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-12-12 16:06:5562.0010,0006,200.00O
2018-12-12 16:06:5363.0010,0006,300.00O
2018-12-12 15:58:3660.801,634993.47O
2018-12-12 15:44:3061.9020,00012,380.00O
2018-12-12 15:34:5960.807,4014,499.81O
View all Faron Pharma trades in real-time

Faron Pharma (FARN) Top Chat Posts

DateSubject
12/12/2018
08:20
Faron Pharma Daily Update: Faron Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FARN. The last closing price for Faron Pharma was 65.50p.
Faron Pharma has a 4 week average price of 57.50p and a 12 week average price of 57.50p.
The 1 year high share price is 915p while the 1 year low share price is currently 51p.
There are currently 31,027,894 shares in issue and the average daily traded volume is 457,387 shares. The market capitalisation of Faron Pharma is £19,547,573.22.
09/11/2018
14:58
spmc: For any one who is interested Evgen Pharma has results of 2 trials due over the next few weeks, share price is starting to rise in anticipation is up 25% already this week. Currently at 17p pre results broker target is £1.10.
22/6/2018
12:13
craigo121: You could argue Director(non exec) buying 48k better than selling his quite considerable stash!! OVER 1 MILLION# Bet he wishes sold few months ago!! The 50k buy looks to me like a desperate attempt into showing confidence in an already depleted share price.
18/6/2018
17:21
ic0gcds00: It hurts to see the share price plummet so much after an £8 placingThe board need to man up and come up with some positves for dhareholders
13/6/2018
17:19
alamaison5: The cash? Just did a placing...and at a much higher price than the share price is now... Imagine the face of the investors when the price crashed. Shouldn't they average down, lol...
04/6/2018
09:26
kirk 6: I did see that share price should be north of £8 now
15/5/2018
09:45
craigo121: 90% drop in share price does not make a bargain! It's dropped 90% for a reason the drug failed they spent 30 million developing not much left in the coffers apart from the 2nd drug 5 million development should equate to 50-60p per share
10/5/2018
14:16
bangers and cash1: Placebo makers, don’t know who to trust some random guy with a short or institutions who decided to buy at many multiples of the share price. Hmmm. Also how can you claim people are ramping when you are flat out lying and posting over and over again, clearly trying to scare people into selling to suit your short. Please leave.
09/5/2018
19:45
deltalo: The bounce has happened but like a bouncing ball the heigh's get lower with each bounce. There is no income to pay for any new trials let alone pay for the rest of the last one. The whole inflation in the share price was on the back of a positive outcome from this trial from the start. What I would like to know is where's the funding coming from and if there is any new trials, how much and how many years will it take. I know something and that's I'm not waiting and I'm not paying. This will fall to its real worth.
03/5/2018
14:35
allonblack: This is so predictable. CEO mouths off in london post period end about trial results on 8 May and then suddenly the share price week before is nothing to see here move along. Buy the dip.
06/4/2018
10:11
paxman: Breq from over at Stocko attended. She said: Some interesting things not obvious from the presentation. Company estimates trial results by May 8. That's the date final 2017 results are announced. Obviously just a target as we all know trial results can be delayed. Mention of further share price gains possible soon. Said in a controlled but positive way. i.e. company still optimistic on trial results. 100,000 treatments available by mid 2019 because company expects demand to be that high. How could doctors not use Traumakine if effective? Breq scanned the Faron website/Linkedin etc. New appointments with a focus on delivering Traumakine so Faron still confident.
Faron Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
FARN
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181213 00:13:15